BIOATLA INC (BCAB) Fundamental Analysis & Valuation

NASDAQ:BCAB • US09077B1044

Current stock price

4.44 USD
-0.22 (-4.72%)
At close:
4.59 USD
+0.15 (+3.38%)
After Hours:

This BCAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BCAB Profitability Analysis

1.1 Basic Checks

  • BCAB had negative earnings in the past year.
  • In the past year BCAB has reported a negative cash flow from operations.
  • In the past 5 years BCAB always reported negative net income.
  • BCAB had a negative operating cash flow in each of the past 5 years.
BCAB Yearly Net Income VS EBIT VS OCF VS FCFBCAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • BCAB has a worse Return On Assets (-431.06%) than 93.81% of its industry peers.
Industry RankSector Rank
ROA -431.06%
ROE N/A
ROIC N/A
ROA(3y)-222.45%
ROA(5y)-150.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCAB Yearly ROA, ROE, ROICBCAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K

1.3 Margins

  • BCAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCAB Yearly Profit, Operating, Gross MarginsBCAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. BCAB Health Analysis

2.1 Basic Checks

  • BCAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BCAB has been increased compared to 1 year ago.
  • The number of shares outstanding for BCAB has been increased compared to 5 years ago.
  • BCAB has a worse debt/assets ratio than last year.
BCAB Yearly Shares OutstandingBCAB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
BCAB Yearly Total Debt VS Total AssetsBCAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • BCAB has an Altman-Z score of -65.68. This is a bad value and indicates that BCAB is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -65.68, BCAB is doing worse than 92.46% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -65.68
ROIC/WACCN/A
WACC9.2%
BCAB Yearly LT Debt VS Equity VS FCFBCAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 0.37 indicates that BCAB may have some problems paying its short term obligations.
  • BCAB's Current ratio of 0.37 is on the low side compared to the rest of the industry. BCAB is outperformed by 92.84% of its industry peers.
  • BCAB has a Quick Ratio of 0.37. This is a bad value and indicates that BCAB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BCAB has a Quick ratio of 0.37. This is amonst the worse of the industry: BCAB underperforms 92.65% of its industry peers.
Industry RankSector Rank
Current Ratio 0.37
Quick Ratio 0.37
BCAB Yearly Current Assets VS Current LiabilitesBCAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. BCAB Growth Analysis

3.1 Past

  • BCAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1433.33%.
  • Looking at the last year, BCAB shows a very negative growth in Revenue. The Revenue has decreased by -81.82% in the last year.
  • Measured over the past years, BCAB shows a very strong growth in Revenue. The Revenue has been growing by 35.99% on average per year.
EPS 1Y (TTM)-1433.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2566.67%
Revenue 1Y (TTM)-81.82%
Revenue growth 3YN/A
Revenue growth 5Y35.99%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.28% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-112.5%
EPS Next 2Y39.5%
EPS Next 3Y25.11%
EPS Next 5Y14.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCAB Yearly Revenue VS EstimatesBCAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2024 2025 2M 4M 6M 8M 10M
BCAB Yearly EPS VS EstimatesBCAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -50 -100

More info and screens

Find the best growth stocksShow best growing peers

1

4. BCAB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BCAB. In the last year negative earnings were reported.
  • Also next year BCAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCAB Price Earnings VS Forward Price EarningsBCAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCAB Per share dataBCAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

  • BCAB's earnings are expected to grow with 25.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.5%
EPS Next 3Y25.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BCAB Dividend Analysis

5.1 Amount

  • BCAB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BCAB Fundamentals: All Metrics, Ratios and Statistics

BIOATLA INC

NASDAQ:BCAB (4/8/2026, 8:17:34 PM)

After market: 4.59 +0.15 (+3.38%)

4.44

-0.22 (-4.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31
Earnings (Next)05-04
Inst Owners22.62%
Inst Owner Change-0.11%
Ins Owners3.92%
Ins Owner Change17.81%
Market Cap367.85M
Revenue(TTM)2.00M
Net Income(TTM)-59.61M
Analysts85.71
Price TargetN/A
Short Float %2.5%
Short Ratio0.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.71%
Min EPS beat(2)10.77%
Max EPS beat(2)34.64%
EPS beat(4)4
Avg EPS beat(4)19.73%
Min EPS beat(4)7.04%
Max EPS beat(4)34.64%
EPS beat(8)8
Avg EPS beat(8)19.54%
EPS beat(12)11
Avg EPS beat(12)16.32%
EPS beat(16)14
Avg EPS beat(16)13.59%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 183.93
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.08
EYN/A
EPS(NY)-46.92
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.02
BVpS-0.44
TBVpS-0.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -431.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-222.45%
ROA(5y)-150.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.37
Quick Ratio 0.37
Altman-Z -65.68
F-Score2
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1433.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2566.67%
EPS Next Y-112.5%
EPS Next 2Y39.5%
EPS Next 3Y25.11%
EPS Next 5Y14.28%
Revenue 1Y (TTM)-81.82%
Revenue growth 3YN/A
Revenue growth 5Y35.99%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.99%
OCF growth 3YN/A
OCF growth 5YN/A

BIOATLA INC / BCAB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIOATLA INC (BCAB) stock?

ChartMill assigns a fundamental rating of 1 / 10 to BCAB.


What is the valuation status for BCAB stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOATLA INC (BCAB). This can be considered as Overvalued.


What is the profitability of BCAB stock?

BIOATLA INC (BCAB) has a profitability rating of 0 / 10.


What is the financial health of BIOATLA INC (BCAB) stock?

The financial health rating of BIOATLA INC (BCAB) is 0 / 10.


What is the earnings growth outlook for BIOATLA INC?

The Earnings per Share (EPS) of BIOATLA INC (BCAB) is expected to decline by -112.5% in the next year.